Articles published by Olema Oncology
Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium
November 25, 2024
From Olema Oncology
Via GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 12, 2024
From Olema Oncology
Via GlobeNewswire
Tickers
OLMA
Olema Oncology to Participate in Upcoming Investor Conferences
November 06, 2024
From Olema Oncology
Via GlobeNewswire
Tickers
OLMA
Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference
August 21, 2024
From Olema Oncology
Via GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 06, 2024
From Olema Oncology
Via GlobeNewswire
Tickers
OLMA
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 08, 2024
From Olema Oncology
Via GlobeNewswire
Tickers
OLMA
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
April 08, 2024
From Olema Oncology
Via GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
March 11, 2024
From Olema Oncology
Via GlobeNewswire
Tickers
OLMA
Olema Oncology to Participate in Upcoming Investor Conferences
February 06, 2024
From Olema Oncology
Via GlobeNewswire
Tickers
OLMA
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
January 08, 2024
From Olema Oncology
Via GlobeNewswire
Tickers
OLMA
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.